Skip to main content

Table 7 Distribution of TLR4 combined genotypes in vitiligo patients and healthy controls

From: TLR4 gene polymorphisms in Egyptian vitiligo patients: insights into emerging association with clinical activity, family history, and response to therapy

TLR4 polymorphisms Case (N = 100) N (%) Control (N = 100)
N (%)
OR (95% CI) p/pc
COMBINED CCCCAG 1 1 1.00 (0.16–16.21) 1.00/NS
CCCTAA 2 1 2.02 (0.18–22.04) 0.57/NS
CCCTAG 6 2 3.13 (0.62–15.89) 0.17/NS
CCCTGG 1 1 1.00 (0.16–16.21) 1.00/NS
CTCCAA 1 2 0.49 (0.04–5.55) 0.57/NS
CTCCAG 2 4 0.49 (0.09–2.74) 0.42/NS
CTCTAA 2 3 0.66 (0.11–4.03) 0.65/NS
CTCTAG 6 9 0.65 (0.22–1.89) 0.42/NS
CTCTGG 1 3 0.33 (0.03–3.19) 0.34/NS
CTTTAA 1 1 1.00 (0.16–16.21) 1.00/NS
CTTTAG 2 2 1.00 (0.14 –7.24) 1.00/NS
TTCCAA 3 5 0.59 (0.14–2.53) 0.48/NS
TTCCAG 8 11 0.70 (0.27–1.83) 0.74/NS
TTCCGG 2 3 0.66 (0.11–4.03) 0.65/NS
TTCTAA 11 10 1.11 (0.45–2.75) 0.82/NS
TTCTAG 29 23 1.34 (0.72–2.85) 0.33/NS
TTCTGG 8 7 1.16 (0.40–3.32) 0.79/NS
TTTTAA 3 2 1.52 (0.25–9.27) 0.65/NS
TTTTAG 8 5 1.65 (0.52–5.24) 0.39/NS
TTTTGG 2 2 1.00 (0.14–7.24) 1.00/NS
  1. OR odds ratio, 95%CI 95% confidence interval. Significant p/pc values if < 0.05, pc Bonferroni corrected p value (number of comparison × p value). NS non-significant
  2. Fisher’s exact: variability in combined genotype with no statistically significant relation